MASLD drug development is limited by models that don't reflect human liver biology. HUB's patient-derived liver organoids retain donor genetics, architecture and physiology.

Download the asset to learn:

• How organoids recapitulate steatosis and fibrosis
• Which readouts support target validation and screening
• Why donor diversity improves translation

Sponsored by